Study of the clinical utility and safety in combination use of the GLP-1 analogue and BG in type 2 diabetic patients
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000009636
- Lead Sponsor
- Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4)or severe renal dysfunction (eGFR: more than 1.5mg/dl) 5)Patients who use of insulin 6)pregnacy 7)Allergy for sitagliptin, nateglinide,liraglutide and exenatide 8)Patients judged by the investigator to be ineligible for some other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method